|
Flu virus, capable of infecting canidae and its application Invention relates to the field of biotechnology and virology. Claimed are isolated strains of the flu virus, capable of infecting canidae and cause respiratory diseases in canidae. Compositions and methods for inducing immune response against the flu virus in canidae are also described. |
|
|
Functional influenza virus-like particles (vlps) Group of inventions refers to medicine, namely biopharmaceutics, and may be used for making vaccines. For this purpose, the vaccine containing the influenza VLPs comprises the Ml, HA and NA proteins of the influenza virus wherein said vaccine induces a long-lived immunity to influenza virus infection in an individual susceptible to influenza, and wherein the MI protein of influenza is prepared of the influenza strain A/Indonesia/5/05. The group of inventions also refers to the use of the vaccine of the composition mention above for the induction of the long-lived immunity to influenza virus infection in an individual. |
|
Method to apply modified flu virus Methods are described to prevent a virus flu infection and detection of efficiency of a flu virus vaccine using a molecule of hemagglutinin (HA) of a flu virus A of subtype H5, immunogenicity of which is increased by replacement of amino acids in the HA sequence. |
|
Protein of flu virus hemagglutinin is disclosed, as well as a molecule of nucleic acid, which codes such protein, a vaccine for treatment or prevention of infections, which are mediated by a flu virus, a set and also methods to produce protein and vaccines. The protein of hemagglutinin H5 of the flu virus is characterised by the fact that in the position 223 of the series it is substituted with asparagine, and the second lysine is built into the position 328. |
|
Immunogenic compositions and methods Described are immunogenic peptides, compositions and methods of their application for therapeutic-prophylactic purposes and/or reduction of intensity against infectious disease, caused by influenza virus, containing two amino acid sequences, different from each other. Described is isolated polynucleotide, which codes immunogenic peptide. Invention includes isolated antibody, specific with respect to peptide. Composition by the invention based on immunogenic peptide is applied for obtaining medication or vaccine. Methods by the invention deals with induction of immunologic response against influenza virus, prevention or control of infection outbreak, cased by influenza virus, in population of mammals, and induction of protective immune response against influenza virus in mammals. |
|
What is constructed is a synthetic gene optimised for expression in plant cells, coding a hybrid protein M2epHBc including an extracellular domain of protein M2 of influenza virus attached to a core antigen of hepatitis B virus. Said protein is produced in plants by constructing a recombinant viral vector on the basis of a genome of potato X-virus. A fragment of the genome of potato X-virus comprising a gene sequence coding M2epHBc has been cloned under the control of a promoter active in plant cells; the whole construct is cloned within a t-DNA region of binary agrobacterial vector. |
|
Recombinant swine influenza virus h1n1 vaccine and method for preparing it Engineered recombinant protein molecule for preparing a recombinant vaccine for an infection caused by swine influenza virus (HlNlv-2009). The molecule consists of a residue of methionine, a sequence of extracellular M2 protein domain of 2 to 24 amino acids and a sequence of a nuclear hepatitis B virus antigen of 4 to 149 amino acids. The molecule is able to form virus-like particles. There are also disclosed a recombinant nucleic acid coding such molecule, a vector for its expression, virus-like particles formed by such molecules and a vaccine based on the prepared virus-like particles. |
|
Invention relates to biotechnology and virology. Compositions and methods used to induce immune response against the influenza virus in canines using novel strains, polynucleotides or polypeptides thereof are described. The invention can be used in veterinary. |
|
Modified influenza virus for monitoring and increasing vaccine efficacy It is described that immunogenicity of hemagglutinin (HA) molecule of influenza virus can be increased by substituting amino acids in the HA sequence. Substituting specific residues in HA such as asparagine introduction in position 223 in HA H5 allows ensuring more sensitive hemagglutination inhibition (HI) test provided by changing receptor specificity and/or ability to antibody-antigen linkage. The HA molecules having such substitutions can find application in creating diagnostic prototype viruses. |
|
Canine influenza virus, compositions containing said virus and application thereof Present invention relates to biotechnology and specifically to isolated canine influenza virus subtype H3N8 which contains HA protein. Described also is a composition which contains an attenuated or inactivated virus and isolated or purified proteins HA, NM, NP, M1, NS1, PA, PB1 and pB2 and fragments thereof. |
|
Immunogenic vaccine composition comprises macromolecular protein structure containing proteins of bird influenza virus HA, NA, and Ml and a carrier or dilution agent. The suggested group of inventions provides safety recombinant vaccine practice and highly immunogenic self-organised macromolecules integrated in plasmamembranes comprising multivariate replicas of structural protein of bird influenza virus demonstrating neutralising epitopes in native conformations. |
Another patent 2513969.